Clinical Trial

EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO

Study acronym: ECMOstase2
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
ECMO (extracorporeal membrane oxygenation) is a life-saving device, used in intensive care to treat severe respiratory or cardiac failure. However, it carries a high risk of serious life-threatening bleeding. Bleeding complications have been attributed to coagulopathy triggered either by the underlying pathology or by the extracorporeal circuit itself, as well as excessive or inappropriate anticoagulation initiated to prevent thrombotic complications. The objective of this cohort is to confirm the interest of the evolution of D-dimers as a prognostic marker of serious bleeding events in patients on veno-venous (VV) or veno-arterial (VA) ECMO, and to determine the threshold.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-17.
Trial Details
NCT Number NCT07039513
Lead Sponsor University Hospital, Strasbourg, France
Conditions ECMO, Mplementation of a Veno-venous VV or Veno-arterial VA, INTENSIVE CARE
Enrollment 100 participants
Start Date 2025-11-27
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-01